New drug approvals for 2019: Synthesis and clinical applications

Shuo Yuan,Bin Yu,Hong-Min Liu

DOI: https://doi.org/10.1016/j.ejmech.2020.112667

IF: 7.088

2020-11-01

European Journal of Medicinal Chemistry

Abstract:<p>48 new drugs including 38 chemical entities (33 new chemical entities, 3 new diagnostic agents, and 2 payloads of antibody drug conjugates) and 10 biologics were approved by the U.S. Food and Drug Administration (FDA) during 2019. These marketed new drugs represent privileged structures and novel action of mechanism, and thus can be served as leads to discover new drugs with the similar biological targets and improved therapeutic efficacy. This review aims to provide an overview regarding the synthetic approaches of 33 new chemical entities approved by the FDA in 2019 and their clinical applications.</p>

chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to summarize the synthetic methods and their clinical applications of 33 new chemical entity drugs approved by the US Food and Drug Administration (FDA) in 2019. These new drugs represent privileged structures and novel mechanisms of action, and thus can be used as lead compounds for the discovery of new drugs with similar biological targets and improved therapeutic effects. Specifically, the paper focuses on the following aspects:

1. **Synthetic methods of new drugs**: The large - scale synthesis routes of 33 new chemical entity drugs are described in detail. These synthetic methods are crucial for the industrial production of drugs.
2. **Clinical applications**: The clinical applications of these new drugs are explored, including their indications, efficacy, and potential side effects.
3. **Drug classification**: These new drugs are classified according to the treatment area, such as anti - infective drugs, cardiovascular drugs, central nervous system drugs, dermatological drugs, hematological drugs, metabolic disease drugs, musculoskeletal disease drugs, and oncology drugs.
4. **Innovation**: Some innovative drugs are emphasized, such as the first nanobody drug, the first anti - sclerosing monoclonal antibody, the first drug for postpartum depression, the first targeted therapy drug for metastatic urothelial carcinoma, and the first treatment method for myelofibrosis.

Through these contents, the paper aims to provide valuable references for medicinal chemists and clinical researchers, and promote the research and development and clinical application of new drugs.